Literature DB >> 2392506

Ontogeny of muscimol effects on locomotor activity, habituation, and pain reactivity in mice.

G Laviola1, E Alleva.   

Abstract

Three hundred and twenty mouse pups of both sexes of the CD-1 outbred strain received IP muscimol and were subsequently assessed for locomotor activity (single Varimex 30-min session) and for hot-plate responding. Muscimol doses were 0.05, 0.1, or 0.2 mg/kg at 8 and 14 days, and 0.1, 0.5, or 1.0 mg/kg at 21, 28, and 35 days. Activity data showed a shift from an immature pattern at 8 and 14 days to an adult-like pattern from day 21 onwards (high initial activity followed by a marked within-session decrement). Muscimol was ineffective on day 8, and depressed activity from day 14 onwards. At 28 days, however, the higher-dose male group showed a non-monotonic trend of activity; that is an initial depression followed by a marked rebound hyperactivity. With regard to hot-plate exposure, muscimol was ineffective at 8 days, while it produced maximal analgesic effects on day 14, followed by a progressive decrease in drug sensitivity. Around day 70, mice of the former 0.1 mg/kg and saline groups were re-tested for locomotor activity and pain reactivity without additional drug treatment. Activity was generally higher in males than in females, and two groups habituated significantly less than the others (females tested in the muscimol state at 8 days and males tested in the saline state at 35 days). Moreover, prior testing at the earliest ages and prior muscimol exposure had additive attenuating effects on pain reactivity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2392506     DOI: 10.1007/bf02245742

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

1.  When to experiment on animals.

Authors:  Patrick Bateson
Journal:  New Sci       Date:  1986-02-20       Impact factor: 0.319

2.  Characteristics of muscimol accumulation in mouse brain after systemic administration.

Authors:  A Maggi; S J Enna
Journal:  Neuropharmacology       Date:  1979-04       Impact factor: 5.250

3.  Muscimol differentially facilitates stereotypy but antagonizes motility induced by dopaminergic drugs: a complex GABA-dopamine interaction.

Authors:  J Scheel-Krüger; A V Christensen; J Arnt
Journal:  Life Sci       Date:  1978-01       Impact factor: 5.037

4.  Antinociceptive and anticonvulsive effect of THIP, a pure GABA agonist.

Authors:  A V Christensen; J J Larsen
Journal:  Pol J Pharmacol Pharm       Date:  1982

5.  Ontogeny of GABA-ergic and dopaminergic mediation of gnawing behavior in the mouse.

Authors:  E Tirelli
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Development of mouse activity, stimulus reactivity, habituation, and response to amphetamine and scopolamine.

Authors:  E Alleva; G Bignami
Journal:  Physiol Behav       Date:  1985-04

7.  GABA, taurine and hypotaurine in developing mouse brain.

Authors:  P Kontro; K M Marnela; S S Oja
Journal:  Acta Physiol Scand Suppl       Date:  1984

8.  Effects of intrathecally administered THIP, baclofen and muscimol on nociceptive threshold.

Authors:  D L Hammond; E J Drower
Journal:  Eur J Pharmacol       Date:  1984-08-03       Impact factor: 4.432

9.  Anti-conflict and depressant effects by GABA agonists and antagonists, benzodiazepines and non-gabergic anticonvulsants on self-stimulation and locomotor activity.

Authors:  L J Herberg; S F Williams
Journal:  Pharmacol Biochem Behav       Date:  1983-10       Impact factor: 3.533

10.  Short-term and delayed behavioral effects of pre- and post-weaning morphine in mice.

Authors:  E Alleva; G Laviola
Journal:  Pharmacol Biochem Behav       Date:  1987-03       Impact factor: 3.533

View more
  1 in total

1.  Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.

Authors:  Laura E Hawley; Faith Prochaska; Megan Stringer; Charles R Goodlett; Randall J Roper
Journal:  Pharmacol Biochem Behav       Date:  2022-05-14       Impact factor: 3.697

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.